Removing obstacles in neuroscience drug discovery: the future path for animal models.
about
sameAs
Methamphetamine-associated psychosis.Negative Allosteric Modulators of Metabotropic Glutamate Receptors Subtype 5 in Addiction: a Therapeutic WindowThe translational study of apathy-an ecological approachThe neurobiology of anhedonia and other reward-related deficitsMapping anhedonia-specific dysfunction in a transdiagnostic approach: an ALE meta-analysisInnovative drugs to treat depression: did animal models fail to be predictive or did clinical trials fail to detect effects?Social stress models in depression research: what do they tell us?Interoception and learning: import to understanding and treating diseases and psychopathologies3D in vitro modeling of the central nervous systemShort and long term measures of anxiety exhibit opposite resultsInduced Pluripotent Stem Cell Models to Enable In Vitro Models for Screening in the Central Nervous SystemInvestigating the mechanism(s) underlying switching between states in bipolar disorderInvestigating the underlying mechanisms of aberrant behaviors in bipolar disorder from patients to models: Rodent and human studies.Developmental rodent models of fear and anxiety: from neurobiology to pharmacology.Histopathologic characterization of the BTBR mouse model of autistic-like behavior reveals selective changes in neurodevelopmental proteins and adult hippocampal neurogenesisTranslational Mouse Models of Autism: Advancing Toward Pharmacological Therapeutics.Optimization of touchscreen-based behavioral paradigms in mice: implications for building a battery of tasks taxing learning and memory functionsAnimal models and conserved processesAn anatomically comprehensive atlas of the adult human brain transcriptomeAnimal models of neuropsychiatric disordersSpontaneous Gamma Activity in Schizophrenia.Animal models of tic disorders: a translational perspective.Developing treatments for cognitive deficits in schizophrenia: the challenge of translation.Anhedonia, avolition, and anticipatory deficits: assessments in animals with relevance to the negative symptoms of schizophreniaA systematic review of physiological methods in rodent pharmacological MRI studies.From basic to clinical neuropharmacology: targetophilia or pharmacodynamics?Mouse pharmacological models of cognitive disruption relevant to schizophrenia.5-hydroxytryptamine 2C receptors in the dorsal striatum mediate stress-induced interference with negatively reinforced instrumental escape behavior.The age of anxiety: role of animal models of anxiolytic action in drug discovery.Assessing learning and memory in pigsA reverse-translational study of dysfunctional exploration in psychiatric disorders: from mice to menAnimal models of virus-induced neurobehavioral sequelae: recent advances, methodological issues, and future prospects.The glutamatergic compounds sarcosine and N-acetylcysteine ameliorate prepulse inhibition deficits in metabotropic glutamate 5 receptor knockout mice.Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia.A quantitative analysis of the effects of qualitatively different reinforcers on fixed ratio responding in inbred strains of mice.Assessment of reward responsiveness in the response bias probabilistic reward task in rats: implications for cross-species translational research.Developing highER-throughput zebrafish screens for in-vivo CNS drug discovery.Association between nicotine withdrawal and reward responsiveness in humans and rats.Relating Translational Neuroimaging and Amperometric Endpoints: Utility for Neuropsychiatric Drug Discovery.The 5-choice continuous performance test: evidence for a translational test of vigilance for mice.
P2860
Q24632172-E61C7774-B16B-462E-A746-1A3EEFBFA19EQ26775243-75FB29DB-5529-4EE0-B82B-CE1AAEF26430Q26781597-E87FB253-80DD-4468-BEB4-2D1494201476Q26853518-8403F2F6-D8CC-4C1C-9C08-642FE9884F3DQ26866062-4417F2FF-8887-43DC-BC48-76F85E9C9C11Q26996411-8EE50C37-6432-405B-83DC-E335974726BCQ27003460-236B817B-0B8D-4177-AE65-723CC8EEF1ECQ27013751-EF711321-76B7-4D87-8836-A7DF0B47D31FQ27026457-66E03B34-3ACF-4C4A-8CA4-A50514FCA7B1Q27342198-D83F303C-7FD5-48DE-93FB-941240A422B6Q28082668-9A913B3F-7261-4017-9041-2F8CCED6501FQ28084519-2137703E-E349-4CC3-B065-0C49684F9C0CQ28085253-0A62888B-BA1F-4BA1-918D-ABEC02B2C792Q28307680-61D6B30B-3610-4595-AE46-31010B173E97Q28390236-9D90EA9D-AFF2-40AD-A194-794CBDBAE439Q28394524-CFCBC4AD-9A5F-454D-BB26-9F7DF2662D4EQ28539980-C676BC3B-F086-45AD-AFB6-E52EFD74642BQ28710144-F738C1E5-F8A2-41A8-8EF3-F06732272563Q29614949-03C72E1F-E246-40C7-B98D-5A08CB7F36DBQ29619899-D1DF9936-9A23-4D39-B9EF-931AA150AE4CQ30377860-F924E7E1-CA16-4394-9DF5-E577D1890FDBQ30395243-123AFA7C-DD25-4724-B566-DDC61E3A93FFQ30396775-FD0D17F9-105A-4BE4-A114-F44B23A73F87Q30413012-54C47327-E0A0-401E-B5BF-28C4F565F4A2Q30420324-A1A96DC7-C120-425A-983B-33741E66AD3FQ30453956-9C319D5D-472C-4D17-9C23-D896F5FC2F26Q30457807-F7F0FAFD-767A-4957-9952-A04B848E77AEQ30460367-3F1ED553-6117-4207-8F6C-3C59AC2F8207Q30462832-38494279-3CAC-426D-A353-25D5BC2FE509Q30476151-208F2CD2-4956-4D8F-B410-A7E3EA867426Q30480638-F11ABAD6-D868-4A8E-BC96-CBBF8E49AC3BQ30481443-07B1EE9D-B4E8-4BBF-9643-39B3301E8767Q30481854-B856F9E9-77C9-43E5-83DD-AF6B27C17FB5Q30489404-4A2B9BA7-5612-4A83-A3AB-21659B63F9ACQ30539665-13753640-0666-48F7-8498-4F912EE292A5Q30543797-4578744D-FA4D-4249-B7DB-23DF32D9D7A4Q30620310-84D90455-66D8-453D-A10B-48D80373AF0EQ30625820-D324EB82-D89F-4D46-9487-A2DBF188D40BQ31064532-50078A39-9211-4D87-BA5A-27619AD8BE8BQ33401264-D3BE9D36-CB01-42D3-993E-6FDE66C2B97E
P2860
Removing obstacles in neuroscience drug discovery: the future path for animal models.
description
2008 nî lūn-bûn
@nan
2008 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
name
Removing obstacles in neuroscience drug discovery: the future path for animal models
@nl
Removing obstacles in neuroscience drug discovery: the future path for animal models.
@ast
Removing obstacles in neuroscience drug discovery: the future path for animal models.
@en
type
label
Removing obstacles in neuroscience drug discovery: the future path for animal models
@nl
Removing obstacles in neuroscience drug discovery: the future path for animal models.
@ast
Removing obstacles in neuroscience drug discovery: the future path for animal models.
@en
prefLabel
Removing obstacles in neuroscience drug discovery: the future path for animal models
@nl
Removing obstacles in neuroscience drug discovery: the future path for animal models.
@ast
Removing obstacles in neuroscience drug discovery: the future path for animal models.
@en
P2093
P2860
P3181
P356
P1476
Removing obstacles in neuroscience drug discovery: the future path for animal models.
@en
P2093
Athina Markou
Mark A Geyer
Mark Tricklebank
Thomas Steckler
P2860
P2888
P3181
P356
10.1038/NPP.2008.173
P407
P577
2008-10-01T00:00:00Z
P5875
P6179
1009868060